Biosion announces exclusive, global license agreement with aclaris therapeutics on two potential first-in-class and best-in-class immunology assets

Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of aclaris therapeutics; additional regulatory and sales milestone payments exceed $900m with tiered single digit sales royalty aclaris therapeutics will be responsible for development and commercialization of bsi-045b, a novel anti-tslp monoclonal antibody, and bsi-502, a novel bispecific antibody that is directed against both tslp and il4r  worldwide (excluding greater china) newark, del. and nanjing, china , nov. 18, 2024 /prnewswire/ -- biosion, inc. (biosion), a global r&d stage biotechnology company, today announced that it has entered into an exclusive license agreement with aclaris therapeutics (nasdaq: acrs) for worldwide rights (excluding greater china) to bsi-045b, a potential first-in-class, clinical-stage, novel anti-tslp monoclonal antibody, and bsi-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both tslp and il4r.
ACRS Ratings Summary
ACRS Quant Ranking